J.M. Remes-Troche, M. Amieva-Balmori, L.F. Uscanga-Domínguez, E. Coss-Adame, R. Bernal-Reyes, R. Carmona-Sánchez, M.R. Francisco, K.R. García-Zermeño, P.C. Gómez-Castaños, O. Gómez-Escudero, M.F. Huerta de la Torre, M.E. Icaza-Chávez, S.E. Martínez-Vázquez, M.P. Milke-García, E. Montijo-Barrios, C.A. Sánchez-Ramírez, E. Toro-Monjaraz, M.A. Valdovinos-Díaz
{"title":"Clinical guideline of the Asociación Mexicana de Gastroenterología for the diagnosis and treatment of lactose ingestion-related disorders","authors":"J.M. Remes-Troche, M. Amieva-Balmori, L.F. Uscanga-Domínguez, E. Coss-Adame, R. Bernal-Reyes, R. Carmona-Sánchez, M.R. Francisco, K.R. García-Zermeño, P.C. Gómez-Castaños, O. Gómez-Escudero, M.F. Huerta de la Torre, M.E. Icaza-Chávez, S.E. Martínez-Vázquez, M.P. Milke-García, E. Montijo-Barrios, C.A. Sánchez-Ramírez, E. Toro-Monjaraz, M.A. Valdovinos-Díaz","doi":"10.1016/j.rgmxen.2026.02.002","DOIUrl":null,"url":null,"abstract":"<div><div>The aim of the present Clinical Guideline of the <em>Asociación Mexicana de Gastroenterología</em> was to establish clear, updated, evidence-based recommendations for the diagnosis and treatment of lactose ingestion-related disorders (LIRDs), to improve diagnostic accuracy and promote effective, patient-centered clinical management. The methodology employed consisted of a Delphi process coordinated by three experts, with the participation of 15 Mexican specialists (gastroenterologists, pediatricians, and nutritionists). Three working groups (epidemiology/definitions, diagnosis, and treatment) were formed that thoroughly reviewed the medical literature published between 2010 and 2025. A total of 26 statements were formulated. The main results included the precise definition of the different LIRD phenotypes (lactase nonpersistence, hypolactasia, clinical lactose intolerance, self-perceived lactose intolerance, and lactose sensitivity); diagnostic test standardization, highlighting the lactose breath test as a highly sensitive noninvasive tool, complemented by genetic studies and biochemical tests; and the recommendation of personalized treatments ranging from the selective reduction of dietary lactose to the use of exogenous enzymes (lactase) and fermented dairy products. Likewise, the importance of avoiding unnecessary dietary restrictions that could compromise calcium and vitamin D intake was emphasized. Altogether, the present consensus provides a comprehensive framework to optimize the clinical care of patients with LIRDs in Mexico.</div></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"91 2","pages":"Pages 231-253"},"PeriodicalIF":0.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de gastroenterologia de Mexico (English)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2255534X26000630","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of the present Clinical Guideline of the Asociación Mexicana de Gastroenterología was to establish clear, updated, evidence-based recommendations for the diagnosis and treatment of lactose ingestion-related disorders (LIRDs), to improve diagnostic accuracy and promote effective, patient-centered clinical management. The methodology employed consisted of a Delphi process coordinated by three experts, with the participation of 15 Mexican specialists (gastroenterologists, pediatricians, and nutritionists). Three working groups (epidemiology/definitions, diagnosis, and treatment) were formed that thoroughly reviewed the medical literature published between 2010 and 2025. A total of 26 statements were formulated. The main results included the precise definition of the different LIRD phenotypes (lactase nonpersistence, hypolactasia, clinical lactose intolerance, self-perceived lactose intolerance, and lactose sensitivity); diagnostic test standardization, highlighting the lactose breath test as a highly sensitive noninvasive tool, complemented by genetic studies and biochemical tests; and the recommendation of personalized treatments ranging from the selective reduction of dietary lactose to the use of exogenous enzymes (lactase) and fermented dairy products. Likewise, the importance of avoiding unnecessary dietary restrictions that could compromise calcium and vitamin D intake was emphasized. Altogether, the present consensus provides a comprehensive framework to optimize the clinical care of patients with LIRDs in Mexico.
Asociación Mexicana de Gastroenterología诊断和治疗乳糖摄入相关疾病的临床指南。
目前的Asociación Mexicana de Gastroenterología临床指南的目的是为乳糖摄入相关疾病(lird)的诊断和治疗建立清晰、最新、基于证据的建议,以提高诊断的准确性,促进有效的、以患者为中心的临床管理。所采用的方法包括由三位专家协调的德尔菲过程,并有15位墨西哥专家(胃肠病学家、儿科医生和营养学家)参与。成立了三个工作组(流行病学/定义、诊断和治疗),彻底审查了2010年至2025年期间发表的医学文献。共拟订了26项声明。主要结果包括准确定义不同的LIRD表型(乳糖酶不耐受、乳糖不耐受、临床乳糖不耐受、自我感觉乳糖不耐受和乳糖敏感性);诊断测试标准化,强调乳糖呼吸测试是一种高度敏感的无创工具,辅以基因研究和生化测试;个性化治疗的建议包括从选择性减少饮食中的乳糖到使用外源性酶(乳糖酶)和发酵乳制品。同样,避免不必要的饮食限制的重要性可能会损害钙和维生素D的摄入量被强调。总之,目前的共识提供了一个全面的框架来优化墨西哥lird患者的临床护理。